Report Overview

The UK Neuromyelitis Optica Spectrum Disorder (NMOSD) Therapeutics market size stood at around USD xx billion in 2020 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.

Neuromyelitis Optica Spectrum Disorder (NMOSD) is previously known as Devic Syndrome, a rare and devastating, autoimmune, inflammatory disorder of the central nervous system (CNS) characterized by severe axonal damage, primarily to the optic nerve and the spinal cord, sudden and unpredictable relapses, also known as attacks. Each relapse results in stepwise accumulation of disability, including blindness, paralysis, bowel and bladder dysfunction, and sometimes leads to premature death. Uncontrolled complement activation triggered by anti-AQP4 autoantibodies is a major underlying mechanism of the disease.

The New England Journal of Medicine (NEJM) published positive data regarding the approval of Soliris by the European Medicines Agency (EMA), as a treatment for patients with NMOSD who are anti-AQP4 antibody-positive. Around 97.9 percent of patients receiving SOLIRIS were relapse-free at 48 weeks compared with 63.2 percent of patients receiving placebo. It has been estimated that NMOSD cases rise up to 430/100,000 of the hospital population. Population-based studies over the past two decades showed that Blacks also have a higher NMOSD prevalence than Whites. A study conducted in the UK reported a prevalence rate of 1.8/100,000 among Blacks. In populations with a higher prevalence, the incidence is also higher.



Market Growth Drivers

The emerging markets and huge investment in research and development are the factors responsible for the growth of the NMOSD market. The emergence of new therapies for the acute phase or prevention of NMOSD creates lucrative opportunities for the market.

The NMOSD market is majorly driven by the rise in the incidence of neuromyelitis optica spectrum disorder. In addition, the emergence of drugs used in the prevention of NMOSD and improvement in healthcare facilities are some of the impacting factors that drive the market growth.

Market Restraints

Nevertheless, less trained expertise or technically skilled professionals coupled with high treatment cost significantly hinder the growth of this market.